key: cord-0991024-twhp9eei
authors: Iijima, Yuki; Okamoto, Tsukasa; Shirai, Tsuyoshi; Mitsumura, Takahiro; Sakakibara, Rie; Honda, Takayuki; Ishizuka, Masahiro; Tateishi, Tomoya; Tamaoka, Meiyo; Aiboshi, Junichi; Otomo, Yasuhiro; Anzai, Tatsuhiko; Takahashi, Kunihiko; Miyazaki, Yasunari
title: MuLBSTA score is a useful tool for predicting COVID-19 disease behavior
date: 2020-10-13
journal: J Infect Chemother
DOI: 10.1016/j.jiac.2020.10.013
sha: cb59d00c08c745effa744fc6fbae741b3f5324d5
doc_id: 991024
cord_uid: twhp9eei

BACKGROUND The prediction of COVID-19 disease behavior in the early phase of infection is challenging but urgently needed. MuLBSTA score is a scoring system that predicts the mortality of viral pneumonia induced by a variety of viruses, including coronavirus, but the scoring system has not been verified in novel coronavirus pneumonia. The aim of this study was to validate this scoring system for estimating the risk of disease worsening in patients with COVID-19. METHODS This study included the patients who were treated between April 1 st and March 13 th , 2020. The patients were classified into mild, moderate, and severe groups according to the extent of respiratory failure. MuLBSTA score was applied to estimate the risk of disease worsening in each severity group and we validated the utility of the scoring system. RESULTS A total of 72 patients were analyzed. Among the 46 patients with mild disease, 17 showed disease progression to moderate or severe disease after admission. The model showed a sensitivity of 100% and a specificity of only 34.5% with a cut-off value of 5 points. Among the 55 patients with mild or moderate disease, 6 deteriorated to severe disease, and the model showed a sensitivity of 83.3% and a specificity of 71.4% with a cut-off value of 11 points. CONCLUSIONS This study showed that MuLBSTA score is a potentially useful tool for predicting COVID-19 disease behavior. This scoring system may be used as one of the criteria to identify high-risk patients worsening to life-threatening status.

admission.

Seventy-two patients who were diagnosed with COVID-19 and treated in our hospital from April 1st to May 13 th , 2020 were enrolled. Severity was defined as follows:

mild for patients who do not need supplemental oxygen, moderate for patients who need supplemental oxygen of less than 4 L/min, and severe for patients who need supplemental oxygen of more than 5 L/min or intubation. The criteria is based on COVID-19 guideline presented by Japanese ministry of Health, Labour and Welfare, in which "mild" for asymptomatic or only complaining cough, "moderate 1" for complicating pneumonia without needing supplemental oxygen, "moderate 2" for complicating pneumonia with needing supplemental oxygen, and "severe" for needing intubation or ICU admission [13] . Namely, "mild" in our definition correspond to "mild" and "moderate 1" in the guideline, "moderate" to "moderate 2", and "severe" to "severe". Multilobular infiltration, lymphopenia, bacterial coinfection, smoking history, hypertension, and age, which are included in MuLBSTA score, 6 infection, +4) + (smoking history: current, +3; ex, +2; never, +0) + (history of hypertension, +2) + (age ≥ 60, +2) [10] . For comparison with the other risk prediction model, the host risk score was estimated as follows: host risk score = (age ≥ 50, +1) + (male, +1) + (presence of hypertension, 1) [9] .

These patients were retrospectively followed to assess their disease progression or deterioration. Disease progression, defined as the increase in severity from mild to moderate or severe, is related to the judgement of hospital admission. Disease deterioration, defined as the development from mild or moderate to severe, is related to ICU referral. We evaluated whether MuLBSTA score significantly predicted these two outcomes.

Continuous variables were expressed as means ± standard deviation (SD Evaluation of disease progression risk in patients with mild disease

Compared to the stable group, the progression group had a significantly higher MuLBSTA score (6.1±4.4 points vs 9.1±3.0 points, p = 0.02) ( Figure 2A , progression group compared to the stable group. There was also a significant difference in the days from symptom onset to admission between the groups (14.1±7.0 days in the stable group vs 9.1±3.4 days in the progression group, p < 0.01). When 5 points was used as the cut-off value for disease progression in ROC curve analysis, the model showed a sensitivity of 100% but a specificity of only 34.5% ( Figure 2B ). In other words, disease progression did not occur if MuLBSTA score was less than 5 points at admission.

Compared to the non-deterioration group, the deterioration group exhibited a significantly higher MuLBSTA score (7.5±4.4 vs 13.5±3.2, p < 0.01) ( Figure 3A , Table 4 ).

Among the parameters of MuLBSTA score, significantly lower lymphocyte counts (1222±605 /μL vs 682±116 /μL, p = 0.01) and significantly higher percentages of bacterial J o u r n a l P r e -p r o o f coinfection (12.2% vs 50.0%, p = 0.05) were seen in the deterioration group compared to the non-deterioration group. In addition, the platelet count was significantly lower (24.8±10.3 ×10 4 /μl vs 14.3±4.3 ×10 4 /μl, p = 0.01) and serum CRP level was significantly higher (5.1±6.7 mg/dl vs 11.5±8.7 mg/dl, p = 0.03) in the deterioration group compared to the non-deterioration group. In this analysis, a significant difference was not observed in the days from symptom onset to admission between the groups (12.1±6.2 days vs 9.3±4.4

days, p = 0.14). When 11 points was used as the cut-off value for the deterioration in ROC curve analysis, the model showed a sensitivity of 83.3% and a specificity of 71.4% (AUC = 0.87) ( Figure 3B ).

Comparison with the host risk score

The host risk score was also applied for evaluation of disease progression and deterioration risks. Although the AUC values of MuLBSTA score determined by ROC curve analysis were higher than those of the host risk score, MuLBSTA score could not predict disease progression or deterioration more accurately than the host risk score with significance ( Figure 4 ).

In the process of modification of MuLBSTA score, we removed bacterial coinfection but added elevation of CRP level. This modification is based on a perspective that judgement of bacterial coinfection is inconsistent between the clinicians, making the scoring model impractical for COVID-19 patients, and that elevation of inflammatory marker such as CRP indicates the possibility of complicating cytokine storm which is one of the J o u r n a l P r e -p r o o f mechanism of disease worsening. The elevation of CRP level was defined as more than 2.18 mg/dl for prediction of the progression risk, and more than 7.72 mg/dl for prediction of the deterioration risk, determined by ROC curve analysis. As a result, the modified MuLBSTA score seemed to exhibit ROC curve with higher AUC value than MuLBSTA score, especially for prediction of disease progression with significance ( Figure 5 , Supplementary Figure 1 ).

This report is the first to validate the utility of MuLBSTA score for predicting disease behavior in patients with COVID-19. We still did not know the recommendations about which patients with mild disease should be hospitalized and which patients with mild or moderate disease is high risk for ICU referral. This scoring system was able to predict these risks and demonstrated that 5 and 11 points were clinically reliable cut-off values. We Eleven points, presented as a cut-off value for deterioration to severe disease, is useful for predicting the possibility of ICU referral accompanied by high mortality. In the preceding study, MuLBSTA score of more than 12 points was presented as a standard for the high 90-day mortality risk among patients with viral pneumonia [10] . The 11 points presented in our study was close to the standard, making it reasonable to interpret as cut-off value for deterioration. Different from the preceding study, 90-day mortality was not assessed in our study because the number of patients who died was only 3 and the observational period was short. Regarding the 3 patients who died, 2 patients with13 points, and 1 patient with only 9 points were included. The patient with 9 points did not have high risk factor of old age, hypertension, or smoking history, resulting in low MuLBSTA score. We speculate his excessive obesity with BMI of 43.7 might be another risk factor concerned.

Among the indexes of MuLBSTA score, the existence of multilobular infiltration, lymphopenia, and bacterial coinfection were significant predictive markers of disease progression and/or deterioration. On the other hand, the other parameters such as smoking history, hypertension, and age, did not reveal clinical significance in either the progression group or deterioration group, though previous reports have presented them as significant mortality risk factors [4, 5, 17] . Moreover, MuLBSTA score could not predict disease progression and deterioration more accurately than the host risk score with significance.

These results may be due to the small sample size in our study. The fact that most of patients with hypertension were already included in the severe group at admission may The impact of the COVID-19 pandemic has resulted in the collapse of the medical care system in many countries worldwide. In such a situation, it is necessary to establish a proper criteria for hospital admission and to prepare medical resources as thoroughly as possible for patients with severe disease. From such a viewpoint, this scoring system may help to overcome the limitation. For example, hospital admission may not be considered for patients with scoring less than 5 points, which had a sensitivity of 100%, thus preventing J o u r n a l P r e -p r o o f these patients from occupying hospital beds. Moreover, recognizing patients with scoring higher than 11 points as those with high risk of needing ICU referral contributes to the ability to prepare for mechanical ventilation or extracorporeal membrane oxygenation (ECMO) in advance.

The limitations of our study are as follows. First, this was a single-institution retrospective study with a small number of participants. However, this is a future suggestion how to utilize this scoring system clinically. Namely, our results may help to establish hospital admission criteria and predict ICU referring, which lead to preventing from collapse of medical care system. Second, the days from symptom onset to admission was significantly longer in the stable group. This means that patients with mild symptoms are likely to be observed at home longer than those with severe symptoms, which introduces a selection bias leading to the differences in MuLBSTA scores. Third, each patient, even those in the same severity group, received different treatments. Because little evidence for effective treatment regimens has been established [21] [22] [23] [24] [25] , it is necessary to verify which treatment is effective or ineffective and ultimately influences disease development. These factors were not considered in this study, and additional prospective studys are needed.

In conclusion, MuLBSTA score is a useful tool for predicting disease behavior in patients with COVID-19. We may use this scoring system as one of the admission criteria and as a risk estimation of ICU referral. However, partial modification is also needed to increase the availability of this model in the near future. J o u r n a l P r e -p r o o f J o u r n a l P r e -p r o o f 

Coronavirus COVID-19 Global Cases by the Center for Systems Science and Engineering

Characteristics of and Important Lessons From the

COVID-19) Outbreak in China: Summary of a Report of 72314 Cases From the Chinese Center for Disease Control and Prevention

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in

China: a retrospective cohort study

Risk Factors Associated with Clinical Outcomes in 323 COVID-19 Hospitalized Patients in Wuhan, China

Obesity in patients younger than 60 years is a risk factor for Covid-19 hospital admission

Risk Factors of Severe Disease and Efficacy of Treatment in Patients Infected with COVID-19: A Systematic Review, Meta-Analysis and Meta-Regression Analysis

Development and Validation of a Clinical Risk Score to Predict the Occurrence of Critical Illness in Hospitalized Patients With COVID-19

Host susceptibility to severe COVID-19 and establishment of a host risk score: findings of 487 cases outside Wuhan

Clinical Features Predicting Mortality Risk in Patients With Viral Pneumonia: The MuLBSTA Score

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study

Baricitinib as potential treatment for 2019-nCoV acute respiratory disease

Japanese ministry of Health, Labour and Welfare. Guide of the medical treatment of 14

Severe lymphopenia in hospitalized patients with influenza virus infection as a marker of a poor outcome

Community-acquired bacterial co-infection predicts severity and mortality in influenza-associated pneumonia admitted patients

Effects of severe acute respiratory syndrome (SARS) coronavirus infection on peripheral blood lymphocytes and their subsets

Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis

The pathogenesis and treatment of the `Cytokine Storm' in COVID-19

Cytokine release syndrome in severe COVID-19

COVID-19: consider cytokine storm syndromes and immunosuppression

Covid-19 -The Search for Effective Therapy

Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study. Engineering (Beijing) 2020

A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19

Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial

Compassionate Use of Remdesivir for Patients with Severe Covid-19